|  |  |
| --- | --- |
| MinutesDrug Utilization Review Board MeetingDATE: March 14, 2024 |  |



**Meeting Purpose:** Quarterly Drug Utilization Board Meeting

Meeting opened at 6:00 p.m. by Timothy Fensky, RPh.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

**Attendance:** Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Sarah M McGee, MD; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

**Absent:** Rebekah Rice, RPh, CDCES

**Agenda Items:**

* Welcome and Introductory Remarks
* Guest Speakers
* Minutes
* Annual Pipeline Continuing Education Program
* Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis
* MHDL Update
* **DUR Operational Update**
* **MassHealth Update**
* **Open Forum**

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow Up** |
| **Guest Speakers** | * Daniel Bassoff, Medical Knowledge Care Team at Sarepta Therapeutics, spoke on Elevidys.
* Jennifer Handt, parent, spoke on Elevidys.
* Brian Denger, parent and advocate at Parent Project Muscular Dystrophies, spoke on Elevidys.

  | **Follow Up**Informational/Advisory |

|  |  |  |
| --- | --- | --- |
| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| **Minutes** | Motion to approve the minutes for December 2023 was made by Christy Stine, MD, PhD and seconded by Timothy Fensky, RPh. | **Follow-up**Minutes are approved. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Annual Pipeline Continuing Education Program** | Annual Pipeline Continuing Education by Dr. Collin Jerrard and Dr. Anhar EldesoukyThe Pipeline Updated provided an overview of clinical and/or regulatory updates regarding select pharmaceutical pipeline agents in late-stage development.   | **Follow-up**Informational/Advisory |
| Action | Discussion * Described recent trends in the FDA approval process
* Compared and contrasted the emerging pipeline agents with current available therapeutic options
* Summarized biosimilar product availability of reference agents over the coming year

Conclusions* Immuno-oncology drugs continued to lead the pack for pipeline drug development.
* Cell and gene therapy approvals continued to accelerate as the number of clinical trials trend upward.
* Biosimilar adoption has been slow, due to numerous factors, such as the COVID-19 pandemic and provider/patient familiarity with reference products.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis** | Pediatric Behavioral Health Medication Initiative Quality Assurance Analysis by Dr. Ashley ChiaraThis overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed the background of PBHMI, existing management, and Therapeutic Class Management (TCM) workgroup involvement
* Discussed recent quality management improvement (QI) and quality assurance (QA) efforts
* Reviewed the annual pediatric behavioral medication utilization data
* Outlined the recommended updates and changes to PBHMI restrictions and prior authorization (PA) criteria

Recommendations* Update antipsychotic age PA criteria
* Update interclass polypharmacy PA criteria
* Update specialist PA criteria
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Drug List (MHDL) Update** | MHDL Update by Dr. Bon VanMHDL overview included new additions, changes in PA status, and related attachment updates to be implemented with a recent publication rollout. | **Follow-up**Informational/Advisory |
| Action | Discussion * There was one addition to the MHDL Drug list effective April 1, 2024.
* As of April 1, 2024, there were four agents added to the MassHealth Supplemental Rebate/Preferred Drug List, as well as additional changes to the MassHealth Acute Hospital Carve-Out Drugs List.
* There were 17 additions to PA status to the MHDL Drug list effective May 6, 2024. Sixteen will require PA while one will not.
* There were several changes to Coverage Status for Pharmacy Billing, Brand Name Preferred Over Generic List; 90-day Initiative; Over the Counter Drug List; Quick Reference Guide; Pharmacy Covered Professional Services List; and Preferred Non-Drug Products Listing
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **DUR Operational Update** | DUR Operational Update by Dr. Patricia LetoDUR operational overview included statistics associated with PA review and PA response, and call center metrics. | **Follow-up**Informational/Advisory |
| Action | Discussion * Operational statistics, including PA and call center metrics up to December 31, 2024, were discussed.
* All metrics met or exceeded service level agreements.
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **MassHealth Update** | MassHealth Update by Dr. Kimberly LenzMassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.  | **Follow-up**Informational/Advisory |
| Action | Discussion * Reviewed current clinical program initiatives
* Provided direct negotiation status update
* Discussed operational updates
 | **Conclusion**The board reviewed and accepted the presentation. |

| **Agenda Item** |  **Discussion** | **Conclusions/Follow- up** |
| --- | --- | --- |
| **Open Forum** | Open Forum | **Follow-up**Informational/Advisory |
| Action | Discussion * This presentation was tabled until the next DUR Board meeting.
 | **Conclusion**N/A |

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_